{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05530655",
            "orgStudyIdInfo": {
                "id": "STUDY00007510_URGUP23077"
            },
            "organization": {
                "fullName": "University of Rochester",
                "class": "OTHER"
            },
            "briefTitle": "A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer",
            "officialTitle": "A Phase I Study to Determine the Preferred Dose of the Angiotensin Converting Enzyme Inhibitor Lisinopril for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "a-study-to-determine-the-preferred-dose-of-the-drug-lisinopril-for-preventing-urinary-toxicity-following-radiotherapy-for-prostate-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-02-20",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-01-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-01-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-09-01",
            "studyFirstSubmitQcDate": "2022-09-01",
            "studyFirstPostDateStruct": {
                "date": "2022-09-07",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-23",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-28",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Hong Zhang",
                "investigatorTitle": "Professor",
                "investigatorAffiliation": "University of Rochester"
            },
            "leadSponsor": {
                "name": "University of Rochester",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Medical College of Wisconsin",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study will establish the preferred dose of lisinopril in men with non-metastatic prostate cancer undergoing radiation treatment. This study will also evaluate the effect of lisinopril on urinary symptoms and the impact of lisinopril on biomarkers and their association with urinary symptoms."
        },
        "conditionsModule": {
            "conditions": [
                "Prostate Cancer",
                "Radiation Toxicity",
                "Urinary Complication"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "EARLY_PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "SUPPORTIVE_CARE",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Control group",
                    "type": "NO_INTERVENTION",
                    "description": "Patients who receive radiation but no intervention"
                },
                {
                    "label": "Intervention group",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Lisinopril Tablets"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Lisinopril Tablets",
                    "description": "This is a dose escalation study of 5 mg, 10 mg and 20 mg doses given once a day.",
                    "armGroupLabels": [
                        "Intervention group"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Mean change in Expanded Prostate Index Composite score",
                    "description": "Patient reported outcomes capturing urinary symptoms will be collected using the Expanded Prostate Index Composite (EPIC) patient reported outcome questionnaire prior to radiation on the first day of treatment, weekly during radiation, and approximately 1 month, 3 months, 6 months, and 12 months after radiation. The EPIC bladder domain score will quantify patient reported urinary symptoms. The EPIC bladder domain consists of 12 items each scored on a Likert scale with an overall score transformed to a 0-100 scale. A higher score indicates worse outcome.",
                    "timeFrame": "baseline to 12 months"
                },
                {
                    "measure": "change in the percentage of patients with positive blood test in urine",
                    "timeFrame": "baseline to 12 months"
                },
                {
                    "measure": "percentage of participants who achieve a dose of 20 mg",
                    "timeFrame": "12 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Have a confirmed diagnosis of adenocarcinoma of the prostate and are candidates for curative-intent external beam radiation (with or without androgen deprivation therapy, ADT) at the Wilmot Cancer Institute Department of Radiation Oncology. Radiotherapy may be either primary, adjuvant or salvage. It may be part of combined treatment with androgen deprivation therapy.\n* Be stage M0 based on the standard of care staging imaging\n* Be able to read English\n* Have the psychological ability and general health that permits completion of the study requirements and required follow up\n* Be \u226518 and \\< 70 years of age\n* Have ECOG performance status of 0 to 2 within 180 days prior to enrollment\n* Have adequate renal function with creatinine clearance \\> 30 mL/min within 30 days prior to registration\n* Have hematologic and hepatic function deemed adequate for planned treatment by the treating investigator within 90 days prior to registration, including:\n* hemoglobin \u22659.0 g/dL, independent of transfusion and/or growth factors\n* platelet count \u2265100,000/\u00b5L independent of transfusion and/or growth factors\n* Have a baseline systolic blood pressure of \\>130.\n\nExclusion Criteria:\n\n* Have received prior pelvic radiotherapy\n* Be taking lisinopril or other RAS modifying drug within two months prior to registration\n* Have had a prior allergic reaction to lisinopril",
            "healthyVolunteers": false,
            "sex": "MALE",
            "genderBased": true,
            "minimumAge": "18 Years",
            "maximumAge": "70 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Therese Smudzin",
                    "role": "CONTACT",
                    "phone": "585-275-7848",
                    "email": "Therese_Smudzin@urmc.rochester.edu"
                }
            ],
            "locations": [
                {
                    "facility": "Wilmot Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Rochester",
                    "state": "New York",
                    "zip": "14642",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Therese Smudzin",
                            "role": "CONTACT",
                            "phone": "585-275-7848",
                            "email": "Therese_Smudzin@urmc.rochester.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.15478,
                        "lon": -77.61556
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011471",
                    "term": "Prostatic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000005834",
                    "term": "Genital Neoplasms, Male"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000005832",
                    "term": "Genital Diseases, Male"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000011469",
                    "term": "Prostatic Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "asFound": "Prostate Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8946",
                    "name": "Genital Neoplasms, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8944",
                    "name": "Genital Diseases, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14333",
                    "name": "Prostatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000017706",
                    "term": "Lisinopril"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000806",
                    "term": "Angiotensin-Converting Enzyme Inhibitors"
                },
                {
                    "id": "D000011480",
                    "term": "Protease Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000959",
                    "term": "Antihypertensive Agents"
                },
                {
                    "id": "D000002316",
                    "term": "Cardiotonic Agents"
                },
                {
                    "id": "D000020011",
                    "term": "Protective Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4134",
                    "name": "Angiotensin-Converting Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M19924",
                    "name": "Lisinopril",
                    "asFound": "Read",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19609",
                    "name": "HIV Protease Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M14343",
                    "name": "Protease Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4277",
                    "name": "Antihypertensive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M5572",
                    "name": "Cardiotonic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M21869",
                    "name": "Protective Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "AnAg",
                    "name": "Antihypertensive Agents"
                },
                {
                    "abbrev": "CaAg",
                    "name": "Cardiotonic Agents"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                }
            ]
        }
    },
    "hasResults": false
}